Physician profile
David A Lin
NPI 1982601043
$3,536.90
in general payments reported to CMS, 2019-2025
30 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $227 · 2021: $322 · 2022: $668 · 2023: $667 · 2024: $863 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $853.63 | 2019-2025 | Mitraclip, Jeti, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $414.40 | 2022-2025 | Lifevest |
| Medtronic, INC. | $254.48 | 2021-2024 | Micra |
| Pfizer INC. | $231.64 | 2021-2025 | |
| Chiesi USA, INC. | $174.59 | 2019 | |
| Novo Nordisk INC | $173.52 | 2024-2025 | Wegovy |
| Edwards Lifesciences Corporation | $163.89 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $131.14 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $119.26 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $113.10 | 2024-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $109.64 | 2019-2022 | |
| Atricure, INC. | $108.92 | 2022-2024 | |
| Biotronik INC. | $105.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $96.36 | 2022-2025 | Eliquis |
| Boston Scientific Corporation | $70.70 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.48 | 2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $48.24 | 2022-2025 | Farxiga |
| Abiomed | $43.46 | 2020-2024 | Impella |
| Inspire Medical Systems, INC. | $33.60 | 2025 | Inspire |
| Amarin Pharma, INC. | $32.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.15 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $24.28 | 2022 | |
| Philips North America LLC | $23.40 | 2024 | (Ck4) Mcot |
| Glaxosmithkline, LLC. | $21.91 | 2025 | Shingrix, Arexvy |
| Csl Behring | $18.14 | 2022 | |
| Baxter Healthcare | $17.90 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $17.18 | 2020 | |
| Penumbra, INC. | $15.31 | 2023 | Indigo System |
| Kiniksa Pharmaceuticals International, Plc | $15.00 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.